CXCL8 and melanoma: I-BET151 inhibits NF-kB activation in melanoma by targeting BRD2, causing cycle arrest, promoting apoptosis, and inhibiting the production of cytokines (e.g., IL6 and IL-8) and chemokines (e.g., CXCL10 and CCL5), which indicates that I-BET151 may have a therapeutic effect on melanoma (4).